Abstract: OBJECTIVE To assess the efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting(CINV), asthenia, lack of appetite, weight lose, after platinum-based chemotherapy. METHODS One hundred nasopharyngeal carcinoma(NPC) patients applied platinum-based chemotherapy were selected and divided into experimental group and control group, 50 patients in each group. Both groups were given tropisetron and the experimental group were given aprepitant 1 h before chemotherapy on the second day and third day. The two group’s nausea and vomiting preventive effect, lack of appetite, asthenia, weight lose, diarrhea, constipation, skin rash, allergy, hand-foot syndrome and neurotoxic sense was compared. RESULTS The effective prevention rate of vomiting in control group was 44%(22 patients), and in experimental group it was 86%(22 patients). The experimental group’s vomiting preventive effect and weight lose were better than the control group(P<0.05). There was no obviously statistically significant for nausea, lack?of appetite, asthenia, diarrhea, constipation, skin rash, allergy, hand-foot syndrome and neurotoxic sense. CONCLUSION Aprepitant treating to NPC patients can be safely and effectively to prevent vomiting and weight lose, but has no effect on nausea and lack of appetite.